SCHEMBL15907693

SCHEMBL15907693

Cc1cnc2c(c1)cc(C#CCO)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 1/20 0.39
PTGDR2 Q9Y5Y4 7/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
HTR6 P50406 1/20 0.34
PDE5A O76074 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
LYN P07948 1/20 0.34
SRC P12931 1/20 0.34
ALDH1A1 P00352 3/20 0.34
PTGDR Q13258 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15907679 0.89 SLC40A1 (0.39) SLC40A1PTGDR2PPARGPPARAPSEN1
SCHEMBL18918826 0.87 ENPP3 (0.43) PTGDR2SRCALDH1A1RECQLLMNA
SCHEMBL15825691 0.79 RORC (0.43)
SCHEMBL15907696 0.76 SLC40A1 (0.45) SLC40A1PTGDR2PPARGPPARAHTR6
SCHEMBL15907666 0.76 SLC40A1 (0.45) SLC40A1PTGDR2PPARGPPARAHTR6
SCHEMBL18918942 0.76 TTK (0.42) HTR6ALDH1A1LMNA
SCHEMBL19349304 0.72 ENPP3 (0.41) PTGDR2PPARGPPARASRCALDH1A1
SCHEMBL15824421 0.70 RORC (0.42)
SCHEMBL26969492 0.70 ALDH3A1 (0.44) SLC40A1PTGDR2PDE5APDE4APDE4B
SCHEMBL27883941 0.70 CYP2C19 (0.47) SLC40A1PTGDR2ALDH1A1RECQLAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349572-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2017-12-07 US disclosed
US-9676748-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-06-13 US disclosed
US-20140213554-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213554-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, PRKCH, PRKACA SLC40A1 4165/4885PTGDR2 2709/4885PPARG 3586/4885
US-20170349572-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, PRKCH, PRKACA SLC40A1 4165/4885PTGDR2 2709/4885PPARG 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.